Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance

NCT04150068 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1-infection

Interventions

DRUG: Oral Lenacapavir
DRUG: Oral Lenacapavir Placebo
DRUG: Subcutaneous Lenacapavir
DRUG: Failing ARV Regimen
DRUG: Optimized Background Regimen (OBR)

Sponsor

Gilead Sciences